Follow the Tirzepatide mechanism of action from a meal
When you eat, gut hormones help the body respond to the meal. Tirzepatide activates two of their receptors, the receiving points on cells. That’s what “dual” means here. It’s one peptide working at two targets.
What it is
Meet GIP and GLP-1
Those are the names of two gut hormones. Tirzepatide is an agonist at their receptors: it switches them on. It helps increase insulin release when blood sugar is high. Insulin is a hormone that helps the body handle sugar.
Appetite matters too. The Zepbound (tirzepatide) label describes GLP-1’s role in appetite and food intake. It says animal studies suggest GIP activity may add to food-intake effects.
Why that matters
Two targets aren’t a score
Lab experiments found that Tirzepatide acts differently at the two receptors. It isn’t an equal push at each one. That’s useful science, but it doesn’t turn the second target into proof of twice the benefit.
To find out what changes in people, we need human trials. Those can measure blood sugar or weight over time. The receptor count alone can’t tell you what will happen in your own care.
What it is
Food leaves the stomach more slowly
That’s called delayed gastric emptying. In an early human study, Tirzepatide slowed it most at first; the effect weakened with repeated treatment. So “it just keeps food in your stomach” leaves out quite a bit.
This is one action of the medicine, alongside its effects on blood sugar and appetite. The research page follows the results in people. A mechanism gives us a reason to test a treatment, rather than certainty about its outcome.
Why that matters
That delay has practical consequences
Birth control pills may work less well. The label advises a non-oral method or an added barrier method for four weeks after starting and after each dose increase. That’s the label’s instruction, not a personal plan from this page.
The label also warns that stomach contents can enter the lungs during general anesthesia or deep sedation. Procedure and prescribing teams need that information. The safety guide covers other cautions; decisions about changing treatment belong with the clinicians involved.